RGEN
Repligen Corp.

1,564
Loading...
Loading...
News
all
press releases
Do Options Traders Know Something About Repligen Stock We Don't?
Investors need to pay close attention to RGEN stock based on the movements in the options market lately.
Zacks·2mo ago
News Placeholder
More News
News Placeholder
Repligen (RGEN) Lags Q2 Earnings Estimates
Repligen (RGEN) delivered earnings and revenue surprises of -7.50% and +3.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Here's Why Repligen (RGEN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·3mo ago
News Placeholder
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?
Zacks·5mo ago
News Placeholder
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
Zacks·5mo ago
News Placeholder
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors BioLife Solutions Appoints Tony J. Hunt to its Board of Directors PR Newswire BOTHELL, Wash., Dec. 16, 2024 BOTHELL, Wash., Dec. 16...
PR Newswire·10mo ago
News Placeholder
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
Repligen Q3 earnings beat expectations with $0.43 EPS and $154.87 million in sales. The company raises 2024 EPS guidance and reports strong growth in CDMO and equipment. Latest Ratings for RGEN...
Benzinga·11mo ago
News Placeholder
Buy Rating Affirmed: Overlooked Long-Term Benefits of Repligen's Potential Maravai Acquisition
Analyst Justin Bowers from Deutsche Bank maintained a Buy rating on Repligen (RGEN Research Report) and increased the price target to $175.00 fro...
TipRanks Financial Blog·1y ago
News Placeholder
Repligen Lowers Guidance On China Weakness, Analyst Expects
Repligen reports Q2 sales of $154.1 million, closely matching the consensus estimate. Adjusted gross margin fell to 49.6% from 50.2%, with an EPS of $0.33. CEO Tony J. Hunt highlights strong Pharma...
Benzinga·1y ago
News Placeholder
Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing
Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the...
Business Wire·1y ago

Latest RGEN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.